{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:49:23Z","timestamp":1790423363648,"version":"4.1.0"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ejmech.2020.112447","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T12:10:58Z","timestamp":1589631058000},"page":"112447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["A comprehensive description of GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists"],"prefix":"10.1016","volume":"200","author":[{"given":"Wenwu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiwei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112447_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2302\/kjm.3.183","article-title":"Effects of sodium glutamate on the nervous system","volume":"3","author":"Hayashi","year":"1954","journal-title":"Keio J. Med."},{"key":"10.1016\/j.ejmech.2020.112447_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.109.002451","article-title":"Glutamate receptor ion channels: structure, regulation, and function","volume":"62","author":"Traynelis","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2020.112447_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn3504","article-title":"NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease","volume":"14","author":"Paoletti","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112447_bib4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nrn.2017.24","article-title":"NMDA receptors: linking physiological output to biophysical operation","volume":"18","author":"Iacobucci","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112447_bib5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1476-5381.2009.00304.x","article-title":"Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential","volume":"157","author":"Mony","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112447_bib6","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2174\/156720512801322564","article-title":"N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer\u2019s disease, vascular dementia and Parkinson\u2019s disease","volume":"9","author":"Olivares","year":"2012","journal-title":"Curr. Alzhrimer Res."},{"key":"10.1016\/j.ejmech.2020.112447_bib7","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.neuint.2004.03.007","article-title":"Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer\u2019s disease","volume":"45","author":"Hynd","year":"2004","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2020.112447_bib8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112447_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1389450013348434","article-title":"NMDA receptor pharmacology: perspectives from molecular biology","volume":"2","author":"Lynch","year":"2001","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2020.112447_bib10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0163-7258(02)00302-9","article-title":"The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications","volume":"97","author":"Loftis","year":"2003","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112447_bib11","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1523\/JNEUROSCI.0829-13.2013","article-title":"Triheteromeric NMDA receptors at hippocampal synapses","volume":"33","author":"Tovar","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2020.112447_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1124\/mol.110.067157","article-title":"Control of assembly and function of glutamate receptors by the amino-terminal domain","volume":"78","author":"Hansen","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112447_bib13","first-page":"533","article-title":"Channel blockers acting at N-Methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore","volume":"61","author":"Kashiwagi","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112447_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0736-5748(90)90070-I","article-title":"Multi-determinate regulation of neuronal survival: neuropeptides, excitatory amino acids and bioelectric activity","volume":"8","author":"Brenneman","year":"1990","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112447_bib15","first-page":"89","article-title":"NMDA antagonists of GluN2B subtype and modulators of GluN2A, GluN2C, and GluN2D subtypes-recent results and developments","volume":"47","author":"Ruppa","year":"2012","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib16","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1161\/01.STR.28.11.2244","article-title":"Effect of CP101, 606, a novel NR2B subunit antagonist of the N-methyl-D-aspartate receptor, on the volume of ischemic brain damage and cytotoxic brain edema after middle cerebral artery occlusion in the feline brain","volume":"28","author":"Di","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.ejmech.2020.112447_bib17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/sj.bjp.0701445","article-title":"Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist","volume":"122","author":"Taniguchi","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112447_bib18","first-page":"239","article-title":"Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors","volume":"163","author":"Steece-Collier","year":"2000","journal-title":"Eep. Neurol."},{"key":"10.1016\/j.ejmech.2020.112447_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.expneurol.2004.05.004","article-title":"The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson\u2019s disease","volume":"188","author":"Nash","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2020.112447_bib20","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03581","article-title":"GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine","volume":"3","author":"Miller","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2020.112447_bib21","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/mds.22169","article-title":"Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism","volume":"23","author":"Nutt","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejmech.2020.112447_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature13548","article-title":"NMDA receptor structures reveal subunit arrangement and pore architecture","volume":"511","author":"Lee","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112447_bib23","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1124\/mol.115.103036","article-title":"A\u00a0novel binding mode reveals two distinct classes of NMDA receptor GluN2B-selective antagonists","volume":"89","author":"Stroebel","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112447_bib24","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1038\/emboj.2009.338","article-title":"Structure of the zinc-bound amino-terminal domain of the NMDA receptor NR2B subunit","volume":"28","author":"Karakas","year":"2009","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2020.112447_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature10180","article-title":"Subunit arrangement and phenylethanolamine binding in GluN1\/GluN2B NMDA receptors","volume":"475","author":"Karakas","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112447_bib26","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1038\/emboj.2011.203","article-title":"Molecular basis of positive allosteric modulation of GluN2B NMDA receptors by polyamines","volume":"30","author":"Mony","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2020.112447_bib27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/ncomms1295","article-title":"Ligand-specific deactivation time course of GluN1\/GluN2D NMDA receptors","volume":"2","author":"Vance","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2020.112447_bib28","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1038\/emboj.2008.140","article-title":"Molecular mechanism of ligand recognition by NR3 subtype glutamate receptors","volume":"27","author":"Yao","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2020.112447_bib29","doi-asserted-by":"crossref","first-page":"113935","DOI":"10.1016\/j.bcp.2020.113935","article-title":"Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine","volume":"177","author":"Hashimoto","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112447_bib30","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/j.1471-4159.2006.03991.x","article-title":"The chemical biology of clinically tolerated NMDA receptor antagonists","volume":"97","author":"Chen","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2020.112447_bib31","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1126\/science.1251915","article-title":"Crystal structure of a heterotetrameric NMDA receptor ion channel","volume":"344","author":"Karakas","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.112447_bib32","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0165-6147(00)89070-7","article-title":"NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release","volume":"16","author":"Mody","year":"1995","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2020.112447_bib33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ceca.2019.04.001","article-title":"Extracellular mild acidosis decreases the Ca2+ permeability of the human NMDA receptors","volume":"80","author":"Plutino","year":"2019","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ejmech.2020.112447_bib34","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1021\/jm990246i","article-title":"4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1\/2B NMDA receptor antagonist","volume":"42","author":"Zhou","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0028-3908(98)00218-4","article-title":"Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn","volume":"38","author":"Boyce","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2020.112447_bib36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.neuropharm.2004.03.011","article-title":"NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats","volume":"47","author":"Wessell","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2020.112447_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuron.2006.09.016","article-title":"A\u00a0hundred years of Alzheimer\u2019s disease research","volume":"52","author":"Hardy","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2020.112447_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2012.11.006","article-title":"The worldwide economic impact of dementia 2010","volume":"9","author":"Wimo","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ejmech.2020.112447_bib39","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.2165\/11595870-000000000-00000","article-title":"Current and emerging drug treatment options for Alzheimer\u2019s disease","volume":"71","author":"Herrmann","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2020.112447_bib40","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10072-013-1316-x","article-title":"Drug development status for Alzheimer\u2019s disease: present scenario","volume":"34","author":"Misra","year":"2013","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejmech.2020.112447_bib41","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1517\/14728222.2014.941286","article-title":"Targeting the NMDA receptor subunit NR2B for treating or preventing age-related memory decline","volume":"18","author":"Wang","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2020.112447_bib42","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1523\/JNEUROSCI.22-09-03628.2002","article-title":"A\u00a0hippocampal NR2B deficit can mimic age-related changes in long-term potentiation and spatial learning in the Fischer 344 rat","volume":"22","author":"Clayton","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2020.112447_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2016.05.025","article-title":"Enhanced attention and impulsive action following NMDA receptor GluN2B-selective antagonist pretreatment","volume":"311","author":"Higgins","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2020.112447_bib44","doi-asserted-by":"crossref","first-page":"11753","DOI":"10.3390\/ijms130911753","article-title":"Neuroprotection for stroke: current status and future perspectives","volume":"13","author":"Minnerup","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2020.112447_bib45","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1747-4949.2012.00770.x","article-title":"Neuroprotection for ischaemic stroke: translation from the bench to the bedside","volume":"7","author":"Sutherland","year":"2012","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.ejmech.2020.112447_bib46","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.neuropharm.2008.01.005","article-title":"Mechanisms of ischemic brain damage","volume":"55","author":"Doyle","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2020.112447_bib47","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1471-4159.1984.tb05396.x","article-title":"Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis","volume":"43","author":"Benveniste","year":"1984","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2020.112447_bib48","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pneurobio.2013.11.006","article-title":"Excitotoxicity and stroke: identifying novel targets for neuroprotection","volume":"115","author":"Lai","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2020.112447_bib49","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S1474-4422(10)70143-5","article-title":"Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment","volume":"9","author":"Baron","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2020.112447_bib50","first-page":"5394021","article-title":"Evaluation of quality of life and satisfaction of patients with neuropathic pain and breakthrough pain: economic impact based on quality of life","volume":"2018","author":"Madariaga Mu\u00f1oz","year":"2018","journal-title":"Pain Res. Treat."},{"key":"10.1016\/j.ejmech.2020.112447_bib51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.euroneuro.2011.05.005","article-title":"Mechanisms of neuropathic pain","volume":"22","author":"Nickel","year":"2012","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.ejmech.2020.112447_bib52","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s12035-009-8086-8","article-title":"Ionotropic glutamate receptors in spinal nociceptive processing","volume":"40","author":"Larsson","year":"2009","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2020.112447_bib53","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1021\/jm060728b","article-title":"N-Methyl-D-aspartate antagonists and neuropathic pain: the search for relief","volume":"50","author":"Childers","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib54","first-page":"895","article-title":"Central sensitization: a generator of pain hypersensitivity by central neural plasticity","volume":"10","author":"Latremoliere","year":"2009","journal-title":"J.\u00a0Pain"},{"key":"10.1016\/j.ejmech.2020.112447_bib55","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","article-title":"Neuropathology of Parkinson disease","volume":"46","author":"Dickson","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejmech.2020.112447_bib56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fncel.2015.00245","article-title":"NMDA receptor GluN2A\/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients","volume":"9","author":"Mellone","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112447_bib57","first-page":"165","article-title":"Changes in surface expression of N-methyl-D-aspartate receptors in the striatum in a rat model of Parkinson\u2019s disease","volume":"8","author":"Gan","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2020.112447_bib58","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.nbd.2018.09.021","article-title":"NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology","volume":"121","author":"Mellone","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2020.112447_bib59","doi-asserted-by":"crossref","first-page":"11608","DOI":"10.1038\/s41598-017-11947-x","article-title":"A\u00a0NMDA-receptor calcium influx assay sensitive to stimulation by glutamate and glycine\/D-serine","volume":"7","author":"Guo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2020.112447_bib60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2217\/nmt.13.77","article-title":"NMDA antagonists as Parkinson\u2019s disease therapy: disseminating the evidence","volume":"4","author":"Majl\u00e1th","year":"2014","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.ejmech.2020.112447_bib61","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11910-013-0409-5","article-title":"Depression and Parkinson\u2019s disease: current knowledge","volume":"13","author":"Marsh","year":"2013","journal-title":"Curr. Neurol. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112447_bib62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neulet.2013.04.045","article-title":"Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests","volume":"546","author":"Andreasen","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2020.112447_bib63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.neures.2015.02.003","article-title":"The NR2B antagonist, ifenprodil, corrects the L-Dopa-induced deficit of bilateral movement and reduces c-Fos expression in the subthalamic nucleus of hemiparkinsonian rats","volume":"96","author":"Igarashi","year":"2015","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.ejmech.2020.112447_bib64","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jagp.2019.06.002","article-title":"Depression symptoms declining among older adults: birth cohort analyses from the rust belt","volume":"28","author":"Sullivan","year":"2020","journal-title":"Am. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.ejmech.2020.112447_bib65","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3389\/fpsyg.2020.00111","article-title":"Adolescent suicide ideation, depression and self-esteem: relationships to a new measure of gender role conflict","volume":"11","author":"O\u2019Beaglaoich","year":"2020","journal-title":"Front. Psychol."},{"key":"10.1016\/j.ejmech.2020.112447_bib66","first-page":"1","article-title":"Different response patterns in hallucinations and delusions to antipsychotic treatment, Nord","volume":"3","author":"Bjarke","year":"2020","journal-title":"J.\u00a0Psychat."},{"key":"10.1016\/j.ejmech.2020.112447_bib67","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jad.2020.01.112","article-title":"Trajectories of depression symptoms from pre-to post-deployment: does previous trauma predict symptom increase?","volume":"266","author":"Karstoft","year":"2020","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.ejmech.2020.112447_bib68","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuropharm.2017.08.006","article-title":"Involvement of extracellular signal-regulated kinase (ERK) in the short and long-lasting antidepressant-like activity of NMDA receptor antagonists (zinc and Ro 25-6981) in the forced swim test in rats","volume":"125","author":"Pochwat","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2020.112447_bib69","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JCP.0b013e31825d70d6","article-title":"A\u00a0randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder","volume":"32","author":"Ibrahim","year":"2012","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2020.112447_bib70","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","article-title":"An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder","volume":"28","author":"Preskorn","year":"2008","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2020.112447_bib71","first-page":"307","article-title":"Glutamatergic modulators in depression, Harv","volume":"26","author":"Henter","year":"2018","journal-title":"Rev. Psychiatr."},{"key":"10.1016\/j.ejmech.2020.112447_bib72","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0014-2999(00)00084-4","article-title":"[H] ifenprodil binding to NMDA receptors in porcine hippocampal brain membranes","volume":"394","author":"H\u00f6fner","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112447_bib73","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jpba.2010.04.014","article-title":"Development of a selective competitive receptor binding assay for the determination of the affinity to NR2B containing NMDA receptors","volume":"53","author":"Schepmann","year":"2010","journal-title":"J.\u00a0Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2020.112447_bib74","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1046\/j.1471-4159.1998.70052147.x","article-title":"In\u00a0vitro binding properties in rat brain of [H] Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits","volume":"70","author":"Mutel","year":"1998","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2020.112447_bib75","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1021\/jm9707986","article-title":"4S)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl] chroman-4, 7-diol: a conformationally restricted analogue of the NR2B subtype-selective NMDA antagonist (1S, 2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol","volume":"41","author":"Butler","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib76","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1021\/cn200013d","article-title":"Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists","volume":"2","author":"Layton","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112447_bib77","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0022-3565(24)37138-1","article-title":"Ro 25\u20136981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in\u00a0vitro","volume":"283","author":"Fischer","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112447_bib78","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1021\/jm030483s","article-title":"NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles","volume":"47","author":"McCauley","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib79","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/jm060420k","article-title":"Selective NR1\/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides","volume":"50","author":"Borza","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib80","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.1021\/acs.jmedchem.5b00897","article-title":"Enantiomerically pure 2-Methyltetrahydro-3-benzazepin-1-ols selectively blocking GluN2B subunit containing N-Methyl-D-aspartate receptors","volume":"58","author":"Tewes","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib81","doi-asserted-by":"crossref","first-page":"111654","DOI":"10.1016\/j.ejmech.2019.111654","article-title":"Design, synthesis and biological evaluation of 1-benzyl-5-oxopyrrolidine-2-carboximidamide derivatives as novel neuroprotective agents","volume":"182","author":"Zhang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib82","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0026-895X(25)13275-6","article-title":"Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors","volume":"44","author":"Williams","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112447_bib83","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0022-3565(25)12992-3","article-title":"Ifenprodil and SL 82.0715 as cerebral antiischemic agents. III. Evidence for antagonistic effects at the polyamine modulatory site within the N-methyl-D-aspartate receptor complex","volume":"253","author":"Carter","year":"1990","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112447_bib84","doi-asserted-by":"crossref","first-page":"9603","DOI":"10.1074\/jbc.271.16.9603","article-title":"Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor","volume":"271","author":"Gallagher","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib85","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pnpbp.2013.06.001","article-title":"Effects of ifenprodil on the antidepressant-like activity of NMDA ligands in the forced swim test in mice","volume":"46","author":"Poleszak","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejmech.2020.112447_bib86","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1021\/jm00114a018","article-title":"Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds","volume":"34","author":"Chenard","year":"1991","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib87","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0149-7634(96)00035-8","article-title":"Glutamate antagonists and Parkinson\u2019s disease: a review of clinical data","volume":"21","author":"Montastruc","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ejmech.2020.112447_bib88","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00213-005-2200-z","article-title":"Ionotropic and metabotropic glutamate receptor structure and pharmacology","volume":"179","author":"Kew","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2020.112447_bib89","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jpba.2013.08.014","article-title":"Metabolism studies of ifenprodil, a potent GluN2B receptor antagonist","volume":"88","author":"Falck","year":"2014","journal-title":"J.\u00a0Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2020.112447_bib90","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1021\/jm00016a017","article-title":"2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-d-aspartate responses","volume":"38","author":"Chenard","year":"1995","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib91","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0014-2999(97)10092-9","article-title":"CP-101,606, a potent neuroprotectant selective for forebrain neurons","volume":"331","author":"Menniti","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112447_bib92","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2015.12.001","article-title":"New targets for rapid antidepressant action","volume":"152","author":"Machado-Vieira","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2020.112447_bib93","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1016\/j.bmcl.2007.08.014","article-title":"Discovery of (-)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro -2(1H)-quinolinone--a potent NR2B-selective N-methyl D-aspartate (NMDA) antagonist for the treatment of pain","volume":"17","author":"Kawai","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib94","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1016\/j.bmcl.2007.08.039","article-title":"Discovery of novel and orally active NR2B-selective N-methyl-D-aspartate (NMDA) antagonists, pyridinol derivatives with reduced HERG binding affinity","volume":"17","author":"Kawai","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib95","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1016\/j.bmcl.2007.08.033","article-title":"Structure-activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites formation","volume":"17","author":"Kawai","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib96","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1021\/jm980235+","article-title":"Structure\u2212activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-Methyl-d-aspartate receptors","volume":"41","author":"Tamiz","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib97","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0960-894X(97)10215-3","article-title":"N-(2-(4-hydroxyphenyl) ethyl)-4-chlorocinnamide: a novel antagonist at the 1A\/2B NMDA receptor subtype","volume":"8","author":"Tamiz","year":"1998","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib98","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1021\/jm990199u","article-title":"Structure\u2212activity relationship of N-(phenylalkyl) cinnamides as novel NR2B subtype-selective NMDA receptor antagonists","volume":"42","author":"Tamiz","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib99","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1021\/jm990148x","article-title":"Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidines","volume":"42","author":"Wright","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib100","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1016\/S0960-894X(99)00482-5","article-title":"Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A\/2B antagonists","volume":"9","author":"Wright","year":"1999","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib101","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1021\/jm000023o","article-title":"Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines","volume":"43","author":"Wright","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib102","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1021\/jm990428c","article-title":"Synthesis of N-substituted 4-(4-hydroxyphenyl)piperidines, 4-(4-hydroxybenzyl)piperidines, and (\u00b1)-3-(4-hydroxyphenyl)pyrrolidines: selective antagonists at the 1A\/2B NMDA receptor subtype","volume":"43","author":"Guzikowski","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib103","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0960-894X(01)00392-4","article-title":"Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin-4-ol: a novel NR1\/2B subtype selective NMDA receptor antagonist","volume":"11","author":"Pinard","year":"2001","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib104","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0960-894X(02)01060-0","article-title":"Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists","volume":"13","author":"Curtis","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib105","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0960-894X(02)01061-2","article-title":"Orally efficacious NR2B-selective NMDA receptor antagonists","volume":"13","author":"Claiborne","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib106","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.brainresbull.2008.08.023","article-title":"Evaluation of behavioural effects of a selective NMDA NR1A\/2B receptor antagonist in the unilateral 6-OHDA lesion rat model","volume":"78","author":"Warraich","year":"2009","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejmech.2020.112447_bib107","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.brainresbull.2008.10.004","article-title":"Behavioural effects of a selective NMDA NR1A\/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions","volume":"78","author":"Truong","year":"2009","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejmech.2020.112447_bib108","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bmcl.2013.12.087","article-title":"Structure-activity relationships of N-substituted 4-(trifluoromethoxy)benzamidines with affinity for GluN2B-containing NMDA receptors","volume":"24","author":"Beinat","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib109","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1016\/j.bmcl.2005.08.110","article-title":"Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists","volume":"15","author":"Borza","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib110","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.bmcl.2007.04.084","article-title":"Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists","volume":"17","author":"Nguyen","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib111","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1016\/S0960-894X(02)00470-5","article-title":"4-Aminoquinolines as a novel class of NR1\/2B subtype selective NMDA receptor antagonists","volume":"12","author":"Pinard","year":"2002","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib112","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0960-894X(03)00007-6","article-title":"2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1\/2B subtype selective NMDA receptor antagonists","volume":"13","author":"B\u00fcttelmann","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib113","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/S0960-894X(03)00232-4","article-title":"4-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1\/2B subtype selective NMDA receptor antagonists","volume":"13","author":"B\u00fcttelmann","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib114","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1016\/S0960-894X(03)00708-X","article-title":"Indole-2-carboxamides as novel NR2B selective NMDA receptor antagonists","volume":"13","author":"Borza","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib115","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bmcl.2006.10.033","article-title":"Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists","volume":"17","author":"Borza","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib116","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/cmdc.200800124","article-title":"Computational studies to discover a new NR2B\/NMDA receptor antagonist and evaluation of pharmacological profile","volume":"3","author":"Gitto","year":"2008","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.112447_bib117","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.bmc.2008.12.058","article-title":"Development of 3-substituted-1H-indole derivatives as NR2B\/NMDA receptor antagonists","volume":"17","author":"Gitto","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib118","doi-asserted-by":"crossref","first-page":"8702","DOI":"10.1021\/jm2008002","article-title":"Synthesis and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-D-aspartate receptors","volume":"54","author":"Gitto","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib119","doi-asserted-by":"crossref","first-page":"10532","DOI":"10.1021\/jm301508d","article-title":"Synthesis and biological characterization of 3-substituted 1H-indoles as ligands of GluN2B-containing N-methyl-D-aspartate receptors. Part 2","volume":"55","author":"Gitto","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib120","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.bmc.2013.12.040","article-title":"Synthesis, modelling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors","volume":"22","author":"Gitto","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib121","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.bmc.2016.02.021","article-title":"Structure-guided design of new indoles as negative allosteric modulators (NAMs) of N-methyl-D-aspartate receptor (NMDAR) containing GluN2B subunit","volume":"24","author":"Buemi","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib122","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1016\/j.bmc.2013.05.044","article-title":"Indole derivatives as dual-effective agents for the treatment of neurodegenerative diseases: synthesis, biological evaluation, and molecular modeling studies","volume":"21","author":"Buemi","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib123","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1016\/j.bmcl.2006.06.002","article-title":"Benzimidazole-2-carboxamides as novel NR2B selective NMDA receptor antagonists","volume":"16","author":"Borza","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib124","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.bmcl.2012.01.108","article-title":"A\u00a0novel series of benzimidazole NR2B-selective NMDA receptor antagonists","volume":"22","author":"Davies","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib125","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1016\/j.bmcl.2004.05.053","article-title":"Oxamides as novel NR2B selective NMDA receptor antagonists","volume":"14","author":"Barta-Szalai","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib126","series-title":"Substituted Imidazol-Pyridazine Derivatives","author":"Buettelmann","year":"2003"},{"key":"10.1016\/j.ejmech.2020.112447_bib127","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1016\/j.bmcl.2011.03.117","article-title":"2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity","volume":"21","author":"Brown","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib128","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acsmedchemlett.7b00309","article-title":"Modulating GluN2B for the treatment of neurological and psychiatric disorders","volume":"8","author":"Kargbo","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112447_bib129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1021\/acsmedchemlett.8b00542","article-title":"1H-Pyrrolo[3,2-b]pyridine GluN2B-selective negative allosteric modulators","volume":"10","author":"Chrovian","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112447_bib130","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/jm060983w","article-title":"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist","volume":"50","author":"Liverton","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib131","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/cmdc.201000005","article-title":"Design, synthesis, and biological evaluation of 3-Benzazepin-1-ols as NR2B-selective NMDA receptor antagonists","volume":"5","author":"Tewes","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.112447_bib132","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1016\/j.bmc.2019.06.035","article-title":"Modification of the 4-phenylbutyl side chain of potent 3-benzazepine-based GluN2B receptor antagonists","volume":"27","author":"Wagner","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib133","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1016\/j.bmc.2010.09.026","article-title":"Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: synthesis and biological evaluation of tetrahydro-3-benzazepine-1, 7-diols","volume":"18","author":"Tewes","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib134","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.bmcl.2015.12.067","article-title":"Role of the phenolic OH moiety of GluN2B-selective NMDA antagonists with 3-benzazepine scaffold","volume":"26","author":"Dey","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib135","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.bmc.2017.12.010","article-title":"2-Methyltetrahydro-3-benzazepin-1-ols - the missing link in SAR of GluN2B selective NMDA receptor antagonists","volume":"26","author":"Dey","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib136","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1016\/j.bmc.2017.07.059","article-title":"Replacement of benzylic hydroxy group by vinyl or hydroxymethyl moiety at the 3-benzazepine scaffold retaining GluN2B affinity","volume":"25","author":"Rath","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib137","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/cmdc.201800214","article-title":"Synthesis and pharmacological evaluation of enantiomerically pure GluN2B selective NMDA receptor antagonists","volume":"13","author":"Borgel","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.112447_bib138","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejmech.2019.05.034","article-title":"Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and sigma 1 receptor antagonists: synthesis, receptor affinity, selectivity and antiallodynic activity","volume":"177","author":"Thum","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib139","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/cmdc.201300547","article-title":"GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists derived from 3-benzazepines: synthesis and pharmacological evaluation of benzo[7]annulen-7-amines","volume":"9","author":"Benner","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.112447_bib140","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1016\/j.bmc.2014.10.004","article-title":"Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines","volume":"22","author":"Gawaskar","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib141","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1016\/j.bmcl.2015.10.076","article-title":"Benzo[7]annulene-based GluN2B selective NMDA receptor antagonists: surprising effect of a nitro group in 2-position","volume":"25","author":"Gawaskar","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib142","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/cmdc.201700311","article-title":"Design, synthesis, pharmacological evaluation and docking studies of GluN2B-selective NMDA receptor antagonists with a Benzo[7]annulen-7-amine scaffold","volume":"12","author":"Gawaskar","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.112447_bib143","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejmech.2016.03.065","article-title":"Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists","volume":"116","author":"Lutnant","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib144","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1039\/C6MD00621C","article-title":"Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?","volume":"8","author":"Shuto","year":"2017","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2020.112447_bib145","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jlcr.3718","article-title":"Synthesis and pharmacological evaluation of fluorinated benzo[7]annulen-7-amines as GluN2B-selective NMDA receptor antagonists","volume":"62","author":"Thum","year":"2019","journal-title":"J.\u00a0Label. Compd. Radiopharm."},{"key":"10.1016\/j.ejmech.2020.112447_bib146","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ejmech.2017.12.054","article-title":"Hydroxymethyl bioisosteres of phenolic GluN2B-selective NMDA receptor antagonists: design, synthesis and pharmacological evaluation","volume":"144","author":"Temme","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib147","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ejmech.2018.08.003","article-title":"Pyridine bioisosteres of potent GluN2B subunit containing NMDA receptor antagonists with benzo[7]annulene scaffold","volume":"157","author":"Zscherp","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib148","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1039\/C8MD00545A","article-title":"Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold","volume":"10","author":"Baumeister","year":"2019","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2020.112447_bib149","doi-asserted-by":"crossref","first-page":"115245","DOI":"10.1016\/j.bmc.2019.115245","article-title":"Thiophene bioisosteres of GluN2B selective NMDA receptor antagonists: synthesis and pharmacological evaluation of [7]annuleno[b]thiophen-6-amines","volume":"28","author":"Baumeister","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib150","doi-asserted-by":"crossref","first-page":"115146","DOI":"10.1016\/j.bmc.2019.115146","article-title":"Impact of hydroxy moieties at the benzo[7]annulene ring system of GluN2B ligands: design, synthesis and biological evaluation","volume":"27","author":"Temme","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib151","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1016\/S0960-894X(03)00713-3","article-title":"1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1\/2B subtype selective NMDA receptor antagonists","volume":"13","author":"Alanine","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib152","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.bmcl.2005.03.025","article-title":"NMDA-NR2B subtype selectivity of stereoisomeric 2-(1,2,3,4-tetrahydro-1-isoquinolyl)ethanol derivatives","volume":"15","author":"Hofner","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib153","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1016\/j.bmcl.2011.07.119","article-title":"Synthesis of a series of gamma-amino alcohols comprising an N-methyl isoindoline moiety and their evaluation as NMDA receptor antagonists","volume":"21","author":"Muller","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib154","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1021\/jm8002153","article-title":"Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists","volume":"51","author":"Tahirovic","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib155","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1016\/j.bmc.2009.05.085","article-title":"Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A\/NR2B N-methyl-D-aspartate receptors","volume":"17","author":"Mosley","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib156","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1016\/j.bmcl.2009.07.028","article-title":"Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA\/NR2B antagonists, Bioorg","volume":"19","author":"McIntyre","year":"2009","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112447_bib157","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1016\/j.bmcl.2010.07.043","article-title":"Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach","volume":"20","author":"Mony","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib158","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1016\/j.bmcl.2017.06.076","article-title":"Discovery of orally bioavailable cyclohexanol-based NR2B-selective NMDA receptor antagonists with analgesic activity utilizing a scaffold hopping approach","volume":"27","author":"Anan","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112447_bib159","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1021\/acsmedchemlett.8b00080","article-title":"BMS-986163, a negative allosteric modulator of GluN2B with potential utility in major depressive disorder","volume":"9","author":"Marcin","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112447_bib160","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejmech.2018.09.010","article-title":"Identification of dual Sigma1 receptor modulators\/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents","volume":"158","author":"Rui","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib161","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejmech.2019.07.012","article-title":"Discovery of new potent dual sigma receptor\/GluN2b ligands with antioxidant property as neuroprotective agents","volume":"180","author":"Zampieri","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib162","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejmech.2018.03.052","article-title":"Design, synthesis and bioevaluation of 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxylic acid derivatives as potent neuroprotective agents","volume":"151","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib163","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.1016\/j.bmc.2010.08.053","article-title":"Synthesis and biological evaluation of radio-iodinated benzimidazoles as SPECT imaging agents for NR2B subtype of NMDA receptor","volume":"18","author":"Fuchigami","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib164","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.ejmech.2011.03.013","article-title":"Synthesis, evaluation and metabolic studies of radiotracers containing a 4-(4-[18F]-fluorobenzyl)piperidin-1-yl moiety for the PET imaging of NR2B NMDA receptors","volume":"46","author":"Labas","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib165","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ejmech.2012.04.011","article-title":"Synthesis and in\u00a0vitro characterization of trans- and cis-[(18)F]-4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]-3-fluoropiperidine-1-carboxylates as new potential PET radiotracer candidates for the NR2B subtype N-methyl-D-aspartate receptor","volume":"53","author":"Koudih","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112447_bib166","doi-asserted-by":"crossref","first-page":"9450","DOI":"10.1021\/acs.jmedchem.9b00812","volume":"62","author":"Ahmed","year":"2019","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420304189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420304189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:11:44Z","timestamp":1759327904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420304189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":166,"alternative-id":["S0223523420304189"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112447","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive description of GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112447"}}